Fesoterodine for the Treatment of Nocturnal Urgency in Patients with Overactive Bladder Syndrome: An Analysis of Responders and Nonresponders

No AccessJournal of UrologyAdult Urology1 Nov 2017Fesoterodine for the Treatment of Nocturnal Urgency in Patients with Overactive Bladder Syndrome: An Analysis of Responders and Nonresponders Johnathan A. Khusid, Jeffrey P. Weiss, Martin O. Carlsson, and Erin K. Mangan Johnathan A. KhusidJohnathan A. Khusid Department of Urology, State University of New York Downstate College of Medicine, Brooklyn, New York More articles by this author , Jeffrey P. WeissJeffrey P. Weiss Department of Urology, State University of New York Downstate College of Medicine, Brooklyn, New York Financial interest and/or other relationship with Ferring, Pfizer, Astellas, Allergan, Elsevier and Symptelligence More articles by this author , Martin O. CarlssonMartin O. Carlsson Biostatistics, Global Product Development, Pfizer Inc., New York, New York Financial interest and/or other relationship with Pfizer. More articles by this author , and Erin K. ManganErin K. Mangan Immunology and Inflammation, Regeneron Pharmaceuticals, Inc., Tarrytown, New York Financial interest and/or other relationship with Pfizer and Regeneron. More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2017.04.098AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: A recent study demonstrated improvement in nocturnal urgency in patients with overactive bladder when treated with fesoterodine. In the current study we aimed to determine which bladder diary parameters predict the response to fesoterodine in these patients. Materials and Methods: Patients with nocturnal urgency completed a 2-week, single-blind placebo run-in followed by 1:1 double-blind randomization to 12 weeks of fesoterodine or placebo. We analyzed bladder diary parameter changes from baseline to week 12, including the actual number of night voids (total number of nocturia episodes), maximum voided volume, nocturnal bladder capacity, Nocturnal Bladder Capacity Index (NBCi) (actual number of night voids – nocturnal urine volume/maximum voided volume – 1), nocturnal urine volume, the nocturia index (nocturnal urine volume/maximum voided volume) and the nocturnal polyuria index (nocturnal urine volume/24-hour volume). Additionally, we analyzed OAB-q (Overactive Bladder Questionnaire) changes. Results: There was a linear relationship between the likelihood of being a responder for NBCi and the nocturia index. Responders had a significant decrease in nocturnal urine volume relative to baseline (–181.7 ml, p <0.01). Neither group showed a significant change in maximum voided volume relative to baseline. There was a significant decrease in NBCi and the nocturia index in responders (–0.82 and –0.61, respectively, each p <0.01). Responders demonstrated improvement in the OAB-q concern, coping, sleep, bother and total score metrics. Conclusions: Patients with nocturnal urgency secondary to overactive bladder syndrome and low nocturnal bladder capacity with a mismatch between nocturnal urine production and bladder capacity may benefit from fesoterodine. Symptom improvement appears to be mediated by increases in typical rather than maximum nocturnal voided volumes. Symptom improvement was associated with improved quality of life. References 1 : An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Neurourol Urodyn2010; 29: 4. Google Scholar 2 : The prevalence and causes of nocturia. J Urol2010; 184: 440. Link, Google Scholar 3 : The prevalence of nocturia and its effect on health-related quality of life and sleep in a community sample in the USA. BJU Int2003; 92: 948. Google Scholar 4 : The economic impact of nocturia. Neurourol Urodyn2014; 33: S10. Google Scholar 5 : Association of nocturia and mortality: results from the Third National Health and Nutrition Examination Survey. J Urol2011; 185: 571. Link, Google Scholar 6 : Prevalence and impact of nocturia in a urogynecologic population. Int Urogynecol J Pelvic Floor Dysfunct2007; 18: 1049. Google Scholar 7 : Nocturia research: current status and future perspectives. Neurourol Urodyn2010; 29: 623. Google Scholar 8 : Efficacy and safety of flexible dose fesoterodine in men and women with overactive bladder symptoms including nocturnal urinary urgency. J Urol2013; 189: 1396. Link, Google Scholar 9 : Validation of the urinary sensation scale (USS). Neurourol Urodyn2011; 30: 360. Google Scholar 10 : Psychometric validation of an overactive bladder symptom and health-related quality of life questionnaire: the OAB-q. Qual Life Res2002; 11: 563. Google Scholar 11 : Nocturia frequency, bother, and quality of life: how often is too often? A population-based study in Finland. Eur Urol2010; 57: 488. Google Scholar 12 : Determining the importance of change in the overactive bladder questionnaire. J Urol2006; 176: 627. Link, Google Scholar 13 : A simple sequentially rejective multiple test procedure. Scand J Stat1979; 6: 65. Google Scholar © 2017 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 198Issue 5November 2017Page: 1119-1123 Advertisement Copyright & Permissions© 2017 by American Urological Association Education and Research, Inc.Keywordscholinergic antagonistsoveractiveurinary bladdertreatment outcomelower urinary tract symptomsnocturiaMetricsAuthor Information Johnathan A. Khusid Department of Urology, State University of New York Downstate College of Medicine, Brooklyn, New York More articles by this author Jeffrey P. Weiss Department of Urology, State University of New York Downstate College of Medicine, Brooklyn, New York Financial interest and/or other relationship with Ferring, Pfizer, Astellas, Allergan, Elsevier and Symptelligence More articles by this author Martin O. Carlsson Biostatistics, Global Product Development, Pfizer Inc., New York, New York Financial interest and/or other relationship with Pfizer. More articles by this author Erin K. Mangan Immunology and Inflammation, Regeneron Pharmaceuticals, Inc., Tarrytown, New York Financial interest and/or other relationship with Pfizer and Regeneron. More articles by this author Expand All Advertisement PDF downloadLoading ...